CASP3 and ovarian cancer: Co-treatment of VPA with DOX led to synergistic suppression of cell viability with an increase in caspase-3 activity and CDKN1A, CCNE1, PARP1, and PARP3 proteins expression in ovarian cancer cell lines [67].